$0.73
+0.08 (+12.67%)
Open$0.69
Previous Close$0.65
Day High$0.76
Day Low$0.63
52W High$4.82
52W Low$2.19
Volume—
Avg Volume320.3K
Market Cap3.05M
P/E Ratio25.28
EPS$0.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+602.2% upside
Current
$0.73
$0.73
Target
$5.14
$5.14
$3.59
$5.14 avg
$6.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 484.7K | 468.9K | 455.7K |
| Net Income | -93,000 | -114,838 | -98,507 |
| Profit Margin | -19.2% | -24.5% | -21.6% |
| EBITDA | -101,936 | -104,145 | -94,610 |
| Free Cash Flow | -84,967 | -104,034 | -103,597 |
| Rev Growth | +6.2% | -0.5% | +16.3% |
| Debt/Equity | 0.77 | 0.85 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |